ITOS250516P9000
- 0.00
- 0.000.00%
ITeos Therapeutics Newsroom
Wells Fargo Maintains ITeos Therapeutics(ITOS.US) With Buy Rating, Cuts Target Price to $16
Piper Sandler Maintains ITeos Therapeutics(ITOS.US) With Buy Rating, Maintains Target Price $16
H.C. Wainwright Maintains ITeos Therapeutics(ITOS.US) With Buy Rating, Maintains Target Price $21
ITeos Therapeutics Analyst Ratings
Wells Fargo Maintains Overweight on ITeos Therapeutics, Lowers Price Target to $16
Piper Sandler Initiates ITeos Therapeutics(ITOS.US) With Buy Rating, Announces Target Price $16
ITeos Therapeutics (ITOS) Gets a Buy From Piper Sandler
J.P. Morgan Maintains ITeos Therapeutics(ITOS.US) With Buy Rating, Cuts Target Price to $15
ITeos Therapeutics Price Target Cut to $15.00/Share From $22.00 by JP Morgan
ITeos Therapeutics Is Maintained at Overweight by JP Morgan
H.C. Wainwright Maintains ITeos Therapeutics(ITOS.US) With Buy Rating, Maintains Target Price $21
Promising Developments and Strategic Updates Drive Buy Rating for ITeos Therapeutics
ITeos Therapeutics Analyst Ratings
Wells Fargo Maintains ITeos Therapeutics(ITOS.US) With Buy Rating, Cuts Target Price to $17
ITeos Therapeutics Analyst Ratings
ITeos Therapeutics: Promising Phase 2 Data Boosts Buy Rating on Lead Asset Belrestotug Combination
H.C. Wainwright Maintains ITeos Therapeutics(ITOS.US) With Buy Rating, Maintains Target Price $21
Wells Fargo Maintains ITeos Therapeutics(ITOS.US) With Buy Rating, Cuts Target Price to $19
Wells Fargo Maintains Overweight on ITeos Therapeutics, Lowers Price Target to $19
ITeos Therapeutics Price Target Maintained With a $21.00/Share by HC Wainwright & Co.